AG-013736 (axitinib)
Sponsors
Pfizer, Memorial Sloan Kettering Cancer Center
Conditions
Acute Myeloid Leukemia (AML)AdenocarcinomaAdenoid Cystic CarcinomaBreast NeoplasmsCarcinoma, Renal CellColorectal NeoplasmsHealthy VolunteersKidney Neoplasms
Phase 1
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
CompletedNCT00076024
Start: 2004-02-29End: 2008-11-30Updated: 2012-06-26
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
CompletedNCT00460603
Start: 2006-01-31End: 2012-11-30Updated: 2013-12-06
Axitinib Pharmacokinetics in Chinese Healthy Volunteers
CompletedNCT00919204
Start: 2009-08-31End: 2009-08-31Updated: 2009-09-21
Phase 2
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
CompletedNCT00071006
Start: 2003-09-30End: 2004-07-31Updated: 2012-06-08
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
CompletedNCT00282048
Start: 2006-03-31End: 2009-06-30Updated: 2012-07-31
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
CompletedNCT00600821
Start: 2008-04-30End: 2012-10-31Updated: 2013-11-08
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
CompletedNCT00615056
Start: 2008-03-31End: 2012-04-30Updated: 2013-04-19
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
CompletedNCT01558661
Start: 2012-03-31End: 2016-08-31Updated: 2017-11-28